Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28073542 | 0.84 | KDM4E (0.38) | SMN1; SMN2CRBNTSHRKDM4ECA2 | |
| SCHEMBL542298 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2CRBNTSHRKDM4ECA2 | |
| SCHEMBL27975998 | 0.79 | CA14 (0.34) | SMN1; SMN2CRBNTSHRCA2NFKB1 | |
| SCHEMBL28073543 | 0.78 | KDM4E (0.33) | SMN1; SMN2KDM4ECA2PTGS1MMP12 | |
| SCHEMBL19821879 | 0.77 | ALDH1A1 (0.33) | KDM4ECA2ALDH1A1CA14 | |
| SCHEMBL15610529 | 0.76 | — | — | |
| SCHEMBL18724483 | 0.73 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL28073408 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL27932093 | 0.73 | TSHR (0.48) | TSHRALDH1A1 | |
| SCHEMBL6253180 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047268-A | A kind of miscellaneous two ring of -5- alkyl [3.3.3] the hendecane class compound of 1- azepines -5- germanium, synthetic method and application | 中国科学技术大学 | 2018-05-18 | — | — | CN | disclosed |
| CN-105693541-B | A kind of synthetic method of ethyldopa | 湖南湘易康制药有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| CN-1228337-C | Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-11-23 | — | — | CN | disclosed |
| CN-1347406-A | Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands | HOFFMANN LA ROCHE (CH) | 2002-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885CRBN 1687/4885TSHR 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.